Analysts Have Conflicting Sentiments on These Healthcare Companies: ARS Pharmaceuticals (SPRY), AnaptysBio (ANAB) and Allakos (ALLK)
Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions
NOTV, BFRI and CPOP Among Pre-market Losers
Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)
Barclays Sticks to Its Sell Rating for Allakos (ALLK)
Allakos Buy Rating: Clinical Promise and Financial Stability Drive Positive Outlook
Allakos | 10-Q: Quarterly report
Allakos Q1 2024 GAAP EPS $(0.81) Misses $(0.44) Estimate
Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.44) by 84.09 percent. This is a 65.31 percent decrease over losses of $(0.49) pe
Allakos 1Q Loss/Shr 81c >ALLK
Allakos 1Q Loss/Shr 81c >ALLK
Press Release: Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology com
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
TD Cowen Remains a Hold on Allakos (ALLK)
Allakos Q4 EPS $(0.71) Misses $(0.47) Estimate
Allakos (NASDAQ:ALLK) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.47) by 51.06 percent. This is a 42 percent decrease over losses of $(0.50) per s
Allakos: Ended 4Q With Approximately $170.8 M in Cash, Cash Equivalents and Investments >ALLK
Allakos: Ended 4Q With Approximately $170.8 M in Cash, Cash Equivalents and Investments >ALLK
No Data